Literature DB >> 2768781

Fatal infantile muscle phosphorylase deficiency.

J M Milstein1, T M Herron, J E Haas.   

Abstract

A premature female infant born of a consanguineous union exhibited joint contractures and signs and symptoms of perinatal asphyxia. A muscle biopsy examined by light microscopic, histochemical, and electron microscopic techniques exhibited changes of muscle phosphorylase deficiency and glycogenosis, identical to those of McArdle's disease. Postmortem ultrastructural examination of liver and heart did not reveal lysosomal storage. This case and one previously reported example of fatal infantile phosphorylase deficiency suggest that the clinical spectrum of McArdle's disease may be broader than previously recognized.

Entities:  

Mesh:

Year:  1989        PMID: 2768781     DOI: 10.1177/088307388900400305

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  4 in total

Review 1.  Respiratory involvement in inherited primary muscle conditions.

Authors:  N Shahrizaila; W J M Kinnear; A J Wills
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

Review 2.  Progress and problems in muscle glycogenoses.

Authors:  S DiMauro; R Spiegel
Journal:  Acta Myol       Date:  2011-10

3.  Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model.

Authors:  Alberto Real-Martinez; Astrid Brull; Jordi Huerta; Guillermo Tarrasó; Alejandro Lucia; Miguel Angel Martin; Joaquin Arenas; Antoni L Andreu; Gisela Nogales-Gadea; John Vissing; Thomas O Krag; Noemi de Luna; Tomàs Pinós
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

4.  Phosphofructo-1-kinase deficiency leads to a severe cardiac and hematological disorder in addition to skeletal muscle glycogenosis.

Authors:  Miguel García; Anna Pujol; Albert Ruzo; Efrén Riu; Jesús Ruberte; Anna Arbós; Anna Serafín; Beatriz Albella; Juan Emilio Felíu; Fátima Bosch
Journal:  PLoS Genet       Date:  2009-08-21       Impact factor: 5.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.